SLU-PP-332

Small molecule Preclinical-heavy

ClassEstrogen-related receptor agonist

Not a peptideOften sold as capsules in peptide catalogs

ThemesMitochondrial / exercise-mimetic rodent work

Human doseNot established

What it is

SLU-PP-332 is a research small molecule that activates estrogen-related receptors (ERRs), published as an exercise-mimetic in mice. Catalog capsules are not a completed human drug.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

An ERR agonist (not a classic peptide) that made headlines as an exercise-mimetic in mice.
The story is endurance-gene activation without the treadmill.
Headline ≠ human protocol. Safety and dose in people are not established like a GLP-1 label.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

ERR activation is intended to push oxidative / mitochondrial gene programs similar to endurance training in animal models.

Possible side effects / caveats

Human AE profile is essentially unknown. Receptor family overlap with endocrine signaling is a reason to stay conservative.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Cited capsule talk	mcg–mg daily figures, vendor-dependent	Oral	Unstandardized; preclinical first